A recent study has observed that combination treatment of class I and class II peptide pulsed HER2-DC1 vaccine with Akt antagonist MK-2206 was able to control the tumor growth in HER2/neu+ BC preclinical model (170). The gene discussed is AKT1; the disease is breast cancer.